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Objective: To test effectiveness of the Early Detection,
Intervention, and Prevention of Psychosis Program in preventing the onset of severe psychosis and improving functioning in a national sample of at-risk youth. Methods: In a
risk-based allocation study design, 337 youth (age 12–25) at
risk of psychosis were assigned to treatment groups based on
severity of positive symptoms. Those at clinically higher risk
(CHR) or having an early first episode of psychosis (EFEP)
were assigned to receive Family-aided Assertive Community
Treatment (FACT); those at clinically lower risk (CLR)
were assigned to receive community care. Between-groups
differences on outcome variables were adjusted statistically
according to regression-discontinuity procedures and evaluated using the Global Test Procedure that combined all
symptom and functional measures. Results: A total of 337
young people (mean age: 16.6) were assigned to the treatment group (CHR + EFEP, n = 250) or comparison group
(CLR, n = 87). On the primary variable, positive symptoms,
after 2 years FACT, were superior to community care (2 df,
p < .0001) for both CHR (p = .0034) and EFEP (p < .0001)
subgroups. Rates of conversion (6.3% CHR vs 2.3% CLR)
and first negative event (25% CHR vs 22% CLR) were low
but did not differ. FACT was superior in the Global Test
(p = .0007; p = .024 for CHR and p = .0002 for EFEP,
vs CLR) and in improvement in participation in work and
school (p = .025). Conclusion: FACT is effective in improving positive, negative, disorganized and general symptoms,
Global Assessment of Functioning, work and school participation and global outcome in youth at risk for, or experiencing very early, psychosis.

Key words: schizophrenia/family psychoeducation/
multifamily group/supported education/supported
employment/assertive community treatment
Introduction
Schizophrenia and the psychotic forms of the major
mood disorders are debilitating, exacting a significant
toll on patients, families, and society. Psychoses rank in
the top 3 most disabling conditions worldwide.1,2 It is
estimated that 2%–3% of the adult population develops
a psychosis, constituting a major burden to public health.
These are devastating disorders for families, who often
assume major caretaking and psychological burdens. It
has been estimated that the annual total costs are $61 billion for schizophrenia alone.3
Recent evidence suggests that early intervention
prior to onset of a psychotic disorder may delay or
prevent onset of frank psychosis and the deterioration in functioning so common in the psychoses.4
A recent comprehensive meta-analysis reported that
the overall risk ratio in 9 preventive clinical trials was
0.34.5 Research to date has built on the observation
that duration of untreated psychosis predicts later
outcomes.6 Even when the individual already meets
criteria for a current psychotic episode, intervention
shortly after onset may improve outcomes by initiating treatment when the individual is more sensitive to
treatment.7,8 Without treatment, many of those found
to be at risk function poorly, even in the absence of a
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psychotic episode.9 For those at risk, early intervention has the potential to prevent onset of a full psychotic disorder; treat the impaired cognitive, social,
and occupational functioning already present; and
alleviate family distress.10–12
One example of these indicated prevention approaches,
the Portland Identification and Early Referral (PIER)
program, is a population-wide system of early detection
and preventive intervention in Greater Portland, ME.13 It
includes extensive community education about the early
signs of psychosis and the potential benefits of early
treatment. Families and young people who meet criteria
for high risk of onset of psychosis receive Family-aided
Assertive Community Treatment (FACT), a package of
interventions consisting of psychoeducational multifamily group (PMFG) therapy, elements of assertive community treatment, supported education and employment,
and psychotropic medication.13–15 Family intervention
is the principal treatment component, based on the evidence for its efficacy in schizophrenia and first episode
and prodromal psychosis.16–19
The Early Detection and Intervention for the
Prevention of Psychosis Program (EDIPPP) was undertaken to build on these findings by testing the effectiveness of the PIER approach across the United States in
a large, ethnically, and geographically diverse population, in 6 typical mental health agencies and settings.
The goal was to evaluate whether early intervention, ie,
prior to onset of psychosis, with young people at clinical high risk could delay or prevent the development
of frank psychosis and reduce functional impairment,
in typical and diverse populations and clinical settings.
Methods
Details of the study design, implementation, assessment,
psychosocial and pharmacological treatments, methods,
and characteristics of the sample have been reported
elsewhere.20
Early Identification
A community outreach and education program targeted
to teachers, school, and college counselors; nurses and
social workers; family and pediatric physicians; and psychiatric practitioners, clinics, and hospitals was undertaken at each site. The objectives were to: (a) increase
knowledge of early warning signs for psychotic disorders,
(b) increase appropriate referrals of youth at risk, (c) create and educate a system of professional and community
member early identifiers, and (d) decrease barriers to early
identification, including stigma.13,21–23 The 6 study sites
conducted extensive, ongoing community and professional education within their respective catchment areas,
beginning in July, 2007. Enrollment began in September,
2007 and continued throughout the study period, ceasing
on June 1, 2010.

Setting
In addition to the Greater Portland, ME, the other 5 sites
were: Sacramento, CA; Ypsilanti, MI; Glen Oaks, NY;
Salem, OR; and Albuquerque, NM.
Inclusion and Exclusion Criteria
Both positive and negative symptoms of psychotic disorders warranted referral for an assessment. All referrals
of adolescents and young adults living in a site’s catchment area were considered for eligibility. A phone screening interview with a trained referrer assessed whether
eligibility was likely. If so, the young person and family were offered a full research and clinical assessment,
which included the Structured Interview for Prodromal
Syndromes (SIPS),24 a component of which is the Scale
of Prodromal Symptoms (SOPS) scale.21,22 Inclusion criteria for the full study sample were established to recruit
clinically lower risk (CLR), clinically higher risk (CHR),
and very early first-episode psychosis (EFEP) participants. Those criteria were: (a) age 12–25, (b) living in the
site’s defined catchment area, and (c) having at least a 1
on any Positive Symptom Scale or a 3 on any Negative
Symptom Scale of the SOPS. For instance, for Unusual
Thought Content (the prodromal version of delusional
ideas), a “1” would be rated if the person experienced
“mind tricks” or a “sense that something is different.” At
a level “3” on Avolition on the Negative Symptoms Scale,
the person would be manifesting “low levels of motivation to participate in goal-directed activities” or “impairment in task initiation and/or persistence.” Youth having
a current frank psychotic episode (a 6 on any Positive
Symptom Scale for longer than 30 consecutive days) were
excluded from the study and assisted in finding other
treatment. Other exclusion criteria included: (a) a prior
episode of psychosis or having received antipsychotic
medication for 30 days or more at a dosage appropriate
to treat a psychotic episode, (b) IQ less than 70, (c) permanent residence outside the catchment area, (d) not an
English speaker or neither parent is an English speaker,
(e) currently a prisoner in the criminal justice system, and
(f) psychotic symptoms due to an acute toxic or medical
etiology.
Intake and Follow-up Assessments
Independent research interviewers conducted all baseline and outcome assessments and were kept blind to
treatment assignment. In addition to the SIPS interview,
baseline assessment included the Global Assessment
of Functioning (GAF)23 and the Structured Clinical
Interview for DSM-IV Axis I Disorders, Clinician
Version (SCID-I/CV).25 Although onset of psychosis
(ie, conversion) has been the focus of previous prevention studies, an additional emphasis of EDIPPP was
on role and social functional outcomes.13,26 Measures
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included the Global Functioning: Social and Global
Functioning: Role Scales (GF:S, GF:R)27 and the
Heinrichs Quality of Life Scale (QLS).28 The Premorbid
Adjustment Scale29 and family history of mental disorder (Family History-Epidemiological)30 were also collected at baseline. SIPS, GAF, GF:R and GF:S, and the
Heinrichs QLS assessments were repeated at the 6-, 12-,
and 24-month points; the SCID was repeated at the
24-month point.
Key outcome variables included (a) conversion to
psychosis, (b) positive and negative symptoms, (c) first
occurrence of a negative event, and (d) changes in social
and occupational functioning. Conversion to psychosis was defined according to the Presence of Psychosis
Scale (POPS) criteria: sustaining any 6 on the Positive
Symptom Scale for 4 or more days per week, at least 1
hour per day for at least 30 days, or demonstrating seriously disorganized or dangerous behavior.21 Negative
events included conversion, relapse, psychiatric hospitalization, incarceration, suicide attempt, completed suicide,
severe self-harm, rape, or assault.
Design
The effectiveness of EDIPPP’s clinical intervention was
tested using a Risk-based Allocation Design (also known
as Regression-Discontinuity).31,32 The range of symptoms
among study subjects was reflected in 3 clinically meaningful subgroups: CLR, CHR, and EFEP. A person’s
baseline score on the primary outcome variable, psychotic
symptoms, determined his or her treatment group. A participant was assigned to the treatment group if the sum
Positive Symptoms score (P-score) was 7 or higher (CHR
and EFEP subgroups), while those below that threshold
were assigned to the CLR comparison group. The EFEP
group was defined as those participants with psychotic
symptoms of 30 days or less duration. A P-score of 7 was
selected as the threshold to maximize the probability that
a participant at high risk for psychosis would be assigned
to the treatment group. Among sum scores of 6–11, 7 had
a high sensitivity score of 0.91 and acceptable specificity of 0.78, the dependent variable being prodromal vs
not prodromal by SOPS criteria. Adjusting statistically
for baseline P-score removes the bias of initial differences between the treatment and comparison groups (see
McFarlane et al20 and the supplementary data for fuller
explanation of methods and assumptions). Consequently,
significant postintervention differences between groups
can be attributed to the intervention itself, where the
intervention effect is represented by a discontinuity in the
regression lines at the cut-point. Compared with randomized assignment, this design has the ethical advantage that
those who most need treatment are assigned to the treatment condition, while participants at lower risk may be
protected from the adverse effects of unnecessary treatment. Youth who were assigned to the CLR comparison
32

group were considered to be at lower risk for developing
psychosis, but not risk free.
Treatment
Both the CHR and EFEP subgroups were provided
FACT, regardless of level of psychosis (see supplementary data for additional detail on FACT).14,15,24 Regarding
psychotropic medication, if attenuated positive symptoms were present or emerged at or above a level of “4” on
the Positive Symptom Scale of the SIPS, aripiprazole was
offered within a dosage range of 1–15 mg. If that was not
tolerated, another antipsychotic medication was offered;
antipsychotic medications were discontinued altogether
if severe side effects persisted. Mood-stabilizing, antidepressant, and anxiolytic medications were provided for
specific symptoms of major mood or anxiety disorders,
using current clinical practice guidelines. The principal
modification to FACT to accommodate younger patients
was to differentiate multifamily groups by age. Thus, 12to 15-year olds were assigned to a “younger” multifamily
group and those in the 17–25 range to an “older” group,
while those in the 15–17 range were assigned on the basis
of developmental age and family preferences.
The CLR group received monthly monitoring through
a phone assessment conducted by a care manager. They
could choose, but were neither encouraged nor assisted,
to obtain treatment elsewhere in the community. As a
subject protection measure, markedly increasing psychotic symptoms were treated with antipsychotic medication by the EDIPPP team until symptoms resolved.
Reliability Assessment, Blinding, and Treatment
Fidelity
Reliability on the SOPS symptom scores, POPS, Heinrichs
QLS, GF:S, and GF:R scales was measured among 37
raters’ scores, compared with criterion scoring by an
experienced psychiatric researcher.20
The interviewers were highly reliable: overall intraclass correlation for ratings of positive symptoms was
.91, and the cross-site range was from .82 to .94. The
reliability of the POPS criterion rating was also good
(κ = 0.68; percent agreement = 93%). Possible bias of
interviewers was assessed at each assessment point and
analyzed to determine whether raters from a given site
evaluated the patient differently than fully blinded raters
from other sites. Among 35 pairs of ratings, correlations
ranged from .90 for positive symptoms to .71 for disorganized symptoms and GAF; all were significant (p < .001).
We concluded that the blinding process was adequate to
prevent biased ratings.
After initial training and during ongoing supervision,
clinicians’ fidelity to the PMFG treatment component was
assessed using the Competency Checklist.33 This measure
had been validated in a trial of the multifamily psychoeducation modality.33 Fidelity was high (mean 85.6% of
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checklist items, ranging from 82% to 90% across sites and
increasing from 80% to 92% during the study) and above
the threshold found to predict treatment effects.33
Analysis
All statistical tests were conducted on an “as assigned”
basis. Two types of outcomes analysis were conducted:
the effect of treatment on (a) time to first negative event
and (b) clinical symptoms and psychosocial functioning. A preliminary test showed that the regression-discontinuity model fit significantly better when the CHR
and EFEP subgroups were distinguished as 2 groups as
opposed to pooled. Therefore, in all subsequent analyses,
we used 2 df tests of significance for FACT intervention
and included 2 indicator variables for CHR and EFEP
subgroups. The effect of treatment on the time to first
negative event was analyzed using Cox regression analysis34 and hazard ratios (HRs) are reported with 95% CIs.
The Cox proportional hazards assumption was tested for
each model variable (baseline P-score, CHR, and EFEP
indicators) and found acceptable (p = .0945, 0.1710, and
0.8816, respectively). The effect of treatment on symptom
and functioning outcomes was analyzed using mixedeffects regression analysis as the primary and the Global
Test Procedure (GTP) as a secondary analysis.35,36 In the
primary analysis, the main effects for the 2 interventiongroup indicators (CHR and EFEP) tested the difference
between those groups and the CLR comparison group,
with emphasis on the 24-month outcome as the primary
endpoint. Indicator variables for time points at which
the outcome was observed were included in the model to
allow estimation of the trajectory of response at 6, 12,
and 24 months and to allow for a nonlinear trajectory;
and visit-by-subgroup interaction terms were included in
the model to allow for arbitrary changes in the intervention effect over these time points. The random intercept
included in the mixed model allows for subject-to-subject
variation in the overall level of the outcome variable
across the follow-up period, though the trajectories
through time were considered nonrandom and estimated
through the fixed-effect time-point indicators.
The intervention-group assignment variable (the sum
P-score) was entered as a covariate in all analyses, as is
necessary in a regression-discontinuity analysis. For analyses of outcome variables other than the positive symptom
scale, the baseline value of each of those variables was also
entered as a covariate. Study site indicators were included
to adjust for variations in outcomes by geographic location. The assumptions of parallel and linear regressions
were tested and found acceptable (p = .64 for group-by-Pscore interactions and p = .63 for quadratic P-score term).
Previous analyses20 had shown that after adjustment for
the baseline value of the positive symptom variable, mean
values of the other measures at baseline were essentially
equivalent, demonstrating the ability of the regression

discontinuity analysis subsequently to furnish unbiased estimates of treatment effects. For descriptive purposes only,
we also report unadjusted mean change scores between
baseline and 24 months with corresponding t tests.
The proportion of subjects who increased their participation in work or school from baseline to 24 months—(a)
from participation in neither work nor school to either
work or school, or both work and school or (b) from
either work or school to both work and school—was
compared using Fisher’s exact test with 95% CIs for the
OR comparing the CLR group with the combined CHR
+ EFEP groups.
A GTP was used to assess whether information from
all 10 variables (SIPS, GAF, etc.) supports a positive
intervention effect across the battery of outcome measures. The procedure used a fixed-effects model and
estimated a single coefficient representing the treatment
effect across the entire battery, while allowing other
terms such as intercepts and time-point effects to vary
from one outcome measure to another. The baseline
assignment variable was included in all outcome measure equations to reflect the regression-discontinuity
design. No adjustment for multiple comparisons due
to the several measures considered is required because
there is only a single intervention effect measured (one
for each intervention subgroup); ie, the model assumes
a single, constant treatment effect for each measure.
The 10 measures were linearly transformed to a scale of
1–10 with reversal of direction for the 4 SIPS variables
in order to put each outcome measure on a uniform
scale in which the assumption of a constant intervention effect is plausible. The intervention effects for the
CHR and EFEP subgroups (each vs the CLR group)
were estimated assuming an unstructured covariance
matrix in both variable space (10 measures) and time (3
time points). Details of the GTP model are contained in
the supplementary data.
Results
Referrals and Participant Sample
Across sites, 520 cases were recommended for orientation, and 392 (75.4%) signed informed consent/assent
and were oriented and assessed (figure 1). Of these, 337
(86.0%) met inclusion criteria and were allocated to treatment, 87 (25.8%) to the CLR comparison group, and 250
(74.2%) to the CHR + EFEP treatment group. Within
the treatment group, 205 cases (82%) were designated as
the CHR subgroup; 45 (18%) were found to have an early
psychosis and were designated as the EFEP subgroup.
The study sample as a whole matched national racial,
ethnic, and socioeconomic distributions rather closely
(table 1).
Fifteen percent of the population was of Hispanic
origin (compared with 15.1% nationally), while 9% was
African-American (compared with 12.8% nationally):
33
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Fig. 1. Flow diagram of participant identification, recruitment, and entry into study.

males predominated, 60%–40%. The mean age for the
CHR and EFEP subsamples—16.4 and 17.9 years,
respectively—was in mid-adolescence, much younger
than the usual age of onset for psychoses, usually found
to be in the range of 20–25 years.37 The between-groups
differences in positive symptom scores reflected the
expected levels, given that the patients were assigned to
groups on the basis of this score. Although mean baseline
GAF scores and diagnoses were also distributed across
groups as expected, social and role functioning scores
(ie, GF:R, GF:S, and QLS) were not, being nearly equal
for all 3 conditions (see table 2). Eighty-four percent of
the CHR and 78% of the CLR groups had current Axis
I disorders; 49% of the CHR group had a major mood
disorder, including 6% with bipolar disorder, and 42%
had an anxiety disorder. Equal proportions of the CHR
and CLR comparison subsamples had been hospitalized
(26% vs 24%), received prior outpatient treatment (75%
vs 72%), and had prior exposure to antipsychotic drugs
(31% vs 27%). Eighty-four percent of the sample was in
school or working, and this did not differ across all 3
assigned subgroups.
34

After treatment assignment at baseline, 76% of the
CLR group sought and received a variety of treatments
in the community, ie, not provided by the study clinicians.
Sixty-three percent received individual therapy, 36% family therapy, 37% supported employment/education, 30%
antipsychotic medication, 47% antidepressants, and 4.8%
mood stabilizers. However, PMFG treatment was only
received by the FACT cohort. Eighty percent of the CHR
and 89% of the EFEP subgroups received the PMFG
component of the FACT intervention.
Symptom Outcomes
For the primary outcome variable, positive symptoms,
FACT was superior, for both CHR and EFEP subgroups,
to the CLR comparison group treatment, controlling for
baseline P-score and site (CHR + EFEP: F = 25.32, p
< .0001; CHR: β = −2.54, SE = 0.86, p = .0034; EFEP:
β = −8.77, SE = 1.40, p < .0001; see figure 2).
For negative symptoms, FACT was superior to the
CLR comparison group, at the trend level for the CHR
subgroup and significantly for the EFEP subgroup,
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Table 1. Baseline Demographic and Clinical Characteristics of the Sample
Comparison (n = 87)

Treatment (n = 250)

Demographic Characteristics

Total (n = 337)

CLR (n = 87)

CHR (n = 205)

EFEP (n = 45)

Statistic

p

Age (mean, SD)
Female, n (%)
Caucasian, n (%)
African-American, n (%)
Asian-American, n (%)
Hispanic, n (%)
Married, n (%)
In school/working, n (%)
Income (dollars)
Mother’s age
Mother’s years education
Father’s age
Father’s years education
SCID-IV diagnoses
No diagnosis
Any Axis I, current or lifetime
Mood disorder
  Bipolar
  Major depression
Anxiety disorder
  PTSD
  
Obsessive–Compulsive
Disorder
   Generalized anxiety disorder
Substance abuse
Psychosis
Other
Psychiatric and medical history
Prior psychiatric hospitalization
Outpatient counseling
Prior head injury
Prior antipsychotic medications

16.56 (3.28)
134 (40)
208 (62)
31 (9)
13 (4)
47 (15)
2 (0.6)
280 (83)
40K–50K
45.79 (8.11)
14.13 (2.53)
49.20 (8.14)
14.68 (2.10)

16.23 (3.18)
26 (30)
62 (71)
5 (6)
4 (5)
8 (9)
1 (0.1)
73 (84)
50K–60K
46.09 (7.41)
14.58 (2.32)
51.16 (7.17)
14.71 (2.10)

16.40 (3.30)
89 (43)
125 (61)
16 (8)
9 (4)
33 (17)
1 (0.5)
171 (84)
40K–50K
45.96 (8.52)
13.91 (2.69)
48.52 (8.59)
14.76 (2.02)

17.93 (3.10)
19 (42)
21 (47)
10 (22)
0 (0)
6 (16)
0 (0)
36 (80)
30K–40K
44.53 (7.45)
14.32 (2.06)
47.81 (7.39)
14.13 (2.41)

F = 4.72
χ2 = 4.80
χ2 = 7.70
χ2 = 10.86
χ2 = 2.09
χ2 = 2.66
χ2 = 0.77
χ2 = 0.40
F = 3.53
F = 0.54
F = 1.80
F = 1.83
F = 0.65

.01
.09
<.03
< .01
.35
.27
.68
.82
.03
.58
.17
.17
.53

47 (14%)
284 (84%)
141 (42%)
16 (5%)
114 (34%)
120 (36%)
28 (8%)
24 (7%)

19 (22%)
67 (78%)
32 (37%)
2 (2%)
27 (31%)
26 (30%)
1 (1%)
3 (3%)

28 (14%)
173 (86%)
101 (50%)
11 (5%)
83 (41%)
84 (42%)
25 (12%)
20 (10%)

0 (0%)
44 (100%)
8 (18%)
3 (7%)
4 (9%)
10 (23%)
2 (5%)
1 (2%)

χ2 = 11.69
χ2 = 11.69
χ2 = 16.56
χ2 = 1.73
χ2 = 17.06
χ2 = 7.50
χ2 = 10.89
χ2 = 5.61

<.01
<.01
<.01
.42
<.01
<.03
<.01
<.07

27 (8%)
28 (8%)
44 (13%)
17 (5%)

5 (6%)
8 (9%)
0 (0%)
5 (6%)

18 (9%)
15 (7%)
3 (1%)
10 (5%)

4 (9%)
5 (11%)
41 (93%)
2 (5%)

χ2 = 0.85
χ2 = 0.82
χ2 = 281.2
χ2 = 0.12

.65
.67
<.01
.94

103 (31%)
240 (72%)
44 (13%)
112 (34%)

21 (24%)
62 (72%)
9 (10%)
23 (27%)

52 (26%)
152 (75%)
29 (14%)
63 (31%)

30 (68%)
26 (59%)
6 (13%)
26 (59%)

χ2 = 32.97
χ2 = 4.48
χ2 = 0.78
χ2 = 15.32

< .01
< .11
.68
< .01

Note: The p values derive from 2 degrees of freedom tests. CHR, clinically higher risk; CLR, clinically lower risk; EFEP, early first-episode
psychosis; PTSD, posttraumatic stress disorder; SCID-IV, Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version IV.

controlling for baseline P-score and site (CHR + EFEP:
F = 3.98, p = .02; CHR: β = −1.90, SE = 1.15, p = .099;
EFEP: β = −4.61, SE = 1.83, p = .012). For disorganized
and general symptoms, the pattern was similar—significant differences for the CHR + EFEP cohort (F = 12.49,
p < .0001 and F = 6.65, p = .0015, respectively), with
significant effects for the EFEP subgroup (β = −3.2345,
SE = 0.8499, p = .0002 and β = −3.8298, SE = 1.1900,
p = .0014, respectively) and trend or nonsignificant differences for the CHR subgroup (β = −0.6566, SE =
0.5373, p = .2226 and β = −1.4034, SE = 0.7335, p =
.0567, respectively; see table 2). Although mean differences in age, gender, race, and family income between
treatment groups was in expected directions, further
adjustment for these variables did not alter the intervention effects. With respect to improvement over time,
the 4 prodromal symptom domains decreased significantly between baseline and 24 months in all 3 groups
(see table 2 and figure 3).

Conversion, Relapse, and Negative Events
In the CHR subgroup, 6.3% experienced conversion to
psychosis over 24 months, compared with 2.3% in the
CLR group. All those in the EFEP subgroup remitted;
11% subsequently relapsed. The number of conversions
was too low for a meaningful survival analysis, and a
chi-squared test was not significant. Twenty-five percent
of the CHR cohort experienced a first negative event, as
did 22% in the CLR cohort and 40% in the EFEP group.
Adjusting for the allocation variable, there was no difference in the distributions of time to first negative event for
the CHR group relative to the CLR control group (HR:
0.94, 95% CI: 0.44–2.04), nor for the EFEP group (HR:
0.90, 95% CI: 0.25–3.20).
Functional and Global Outcomes
Compared with CLR, FACT had significantly better GAF outcomes for the CHR + EFEP cohort,
35

36
Mean (SD)

(n = 56)

(n = 87)
Mean (SD)

6 mo

Baseline

Mean (SD)

(n = 57)

(n = 87)
Mean (SD)

12 mo

Baseline

(b) Adjusted clinical and functional outcomes at baseline and 12 mo
SIPS Positive Symptomsc
15.5 (na)
9.7 (1.0)
SIPS Negative Symptomsc
14.5 (1.4)
11.6 (1.2)
SIPS Disorganized Symptomsc
7.7 (0.6)
4.0 (0.6)
SIPS General Symptomsc
11.6 (1.0)
7.1 (0.9)
Global Assessment of Functioningc
36.7 (2.8)
53.5 (3.2)
GF:Role
4.6 (0.3)
6.1 (0.5)
GF:Social
5.6 (0.3)
7.1 (0.3)
QLS Instrumental
2.7 (0.4)
3.7 (0.4)
QLS Interpersonal
3.3 (0.3)
4.0 (0.2)
QLS Intrapsychic
3.6 (0.2)
4.1 (0.2)

Outcome Variable

Adjusted Scoresa

(a) Adjusted clinical and functional outcomes at baseline and 6 mo
SIPS Positive Symptomsc
15.5 (na)
9.74 (1.0)
SIPS Negative Symptomsc
14.5 (1.4)
11.03 (1.2)
SIPS Disorganized Symptomsc
7.7 (0.6)
4.10 (0.6)
SIPS General Symptomsc
11.6 (1.0)
7.08 (0.9)
Global Assessment of Functioningc
36.7 (2.8)
54.78 (3.1)
GF:Role
4.6 (0.3)
6.21 (0.5)
GF:Social
5.6 (0.3)
6.87 (0.3)
QLS Instrumental
2.7 (0.4)
3.70 (0.4)
QLS Interpersonal
3.3 (0.3)
4.05 (0.2)
QLS Intrapsychic
3.6 (0.2)
4.04 (0.2)

Outcome Variable

Adjusted Scoresa

CLR

Table 2. Symptoms and Functional Scores Across Study Time Points

−37.6
−20.2
−48.4
−39.1
+45.8
+32.7
+27.0
+38.5
+24.4
+13.2

% Change

−37.2
−23.9
−47.0
−39.2
+49.3
+35.3
+23.1
+38.2
+24.4
+12.6

% Change

b

b

10.24 (1.1)
11.46 (1.4)
4.05 (0.7)
6.77 (1.5)
54.15 (3.6)
5.66 (0.6)
7.25 (0.3)
3.87 (0.5)
4.29 (0.3)
4.20 (0.3)

Mean (SD)

Mean (SD)
15.5 (na)
14.6 (0.6)
6.9 (0.3)
11.7 (0.4)
37.9 (1.2)
5.3 (0.2)
5.9 (0.1)
3.1 (0.2)
3.4 (0.1)
3.6 (0.1)

(n = 147)

12 mo

(n = 205)

Baseline

9.58 (0.4)
10.75 (0.5)
3.87 (0.3)
7.14 (1.1)
51.84 (1.4)
5.85 (0.2)
6.70 (0.1)
3.75 (0.2)
3.91 (0.1)
4.09 (0.1)

Mean (SD)

Mean (SD)
15.5 (na)
14.6 (0.6)
6.9 (0.3)
11.7 (0.4)
37.9 (1.2)
5.3 (0.2)
5.9 (0.1)
3.1 (0.2)
3.4 (0.1)
3.6 (0.1)

(n = 156)

6 mo

(n = 205)

Baseline

CHR

−33.9
−21.3
−40.9
−42.0
+42.8
+6.6
+22.8
+25.4
+26.4
+16.6

% Change

−38.2
−26.2
−43.4
−38.8
+36.7
+10.2
+13.5
+21.4
+15.0
+13.7

% Change

15.5 (na)
13.6 (1.0)
7.6 (0.5)
11.2 (0.7)
31.1 (2.1)
5.0 (0.4)
6.3 (0.2)
3.1 (0.3)
3.6 (0.2)
3.6 (0.2)

Mean (SD)

(n = 45)

Baseline

15.5 (na)
13.6 (1.0)
7.6 (0.5)
11.2 (0.7)
31.1 (2.1)
5.0 (0.4)
6.3 (0.2)
3.1 (0.3)
3.6 (0.2)
3.6 (0.2)

Mean (SD)

(n = 45)

Baseline

EFEP

2.0 (0.8)***
6.1 (1.0)**
1.2 (0.4)***
3.7 (0.8)*
63.8 (2.6)*
6.2 (0.4)
7.0 (0.2)
3.7 (0.3)
4.4 (0.2)
4.5 (0.2)

Mean (SD)

(n = 36)

12 mo

1.80 (1.0)***
6.14 (1.4)**
0.97 (0.6)***
3.82 (1.0)*
63.45 (3.5)
5.84 (0.6)
6.49 (0.3)
3.57 (0.5)
4.14 (0.3)
4.36 (0.3)

Mean (SD)

(n = 35)

6 mo

−87.4
−55.3
−84.4
−67.3
+105.0
+23.2
+10.7
+17.4
+22.8
+23.7

% Change

−88.4
−54.8
−87.2
−65.8
+104.0
+16.3
+3.2
+13.6
+14.8
+21.0

% Change
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Mean (SD)

(n = 55)

(n = 87)
Mean (SD)

24 mo

Baseline

CLR

−40.5
−28.7
−48.2
−49.0
+53.5
+21.3
+24.2
+37.7
+28.9
+18.2

% Changeb
15.5 (na)
14.6 (0.6)
6.9 (0.3)
11.7 (0.4)
37.9 (1.2)
5.3 (0.2)
5.9 (0.1)
3.1 (0.2)
3.4 (0.1)
3.6 (0.1)

Mean (SD)

(n = 205)

Baseline

CHR

6.7 (0.4)**
8.4 (0.6)**
3.4 (0.3)**
4.5 (0.9)**
58.2 (1.5)**
6.0 (0.3)**
7.2 (0.1)**
4.0 (0.2)**
4.4 (0.1)**
4.4 (0.1)**

Mean (SD)

(n = 134)

24 mo

−56.9
−42.1
−51.0
−61.1
+53.4
+13.6
+21.4
+28.8
+28.5
+23.3

% Change
15.5 (na)
13.6 (1.0)
7.6 (0.5)
11.2 (0.7)
31.1 (2.1)
5.0 (0.4)
6.3 (0.2)
3.1 (0.3)
3.6 (0.2)
3.6 (0.2)

Mean (SD)

(n = 45)

Baseline

EFEP

0.5 (0.8)***
5.7 (1.0)***
0.8 (0.5)***
2.1 (0.6)***
64.5 (2.6)**
5.9 (0.5)**
7.1 (0.2)**
3.7 (0.4)**
4.4 (0.2)**
4.6 (0.2)**

Mean (SD)

(n = 33)

24 mo

−97.1
−57.9
−89.7
−81.1
+107.4
+17.4
+12.8
+18.4
+21.7
+28.2

% Change

Notes: na, not applicable; QLS, Quality of Life Scale; SIPS, Structured Interview for Prodromal Syndromes. Abbreviations are explained in the first footnote to table 1.
a
Adjusted to baseline Positive Symptoms score of 15.5. Means are averages of site-specific adjusted means weighted by the total number of subjects within sites at baseline.
Differences in adjusted means between groups equal the regression-discontinuity intervention coefficients. Outcome variables other than Positive Symptoms additionally
adjusted to overall mean of baseline score, as follows: Negative Symptoms = 13.39; Disorganized Symptoms = 5.50; General Symptoms = 10.43; Global Assessment of
Functioning = 41.20; GF:Role = 5.41; GF:Social = 6.12; QLS Instrumental = 3.27; QLS Interpersonal = 3.54; QLS Intrapsychic = 3.71.
b
Percentage changes are calculated on exact means and may not agree with percentage changes in the table due to round-off. Positive Symptoms score is the sum of 5 items;
Negative Symptoms score is the sum of 6 items; Disorganized Symptoms score is the sum of 4 items; General Symptoms Score is the sum of 4 items.
c
Comparisons among 3 groups are jointly significant with 2 degree of freedom tests at p <.05 for all 4 SIPS outcomes and the Global Assessment of Functioning.
*p < .05, **p < .01, ***p < .001, all individual group comparisons are with respect to the CLR group.

(c) Adjusted clinical and functional outcomes at baseline and 24 mo
SIPS Positive Symptomsc
15.5 (na)
9.2 (1.0)
SIPS Negative Symptomsc
14.5 (1.4)
10.3 (1.3)
SIPS Disorganized Symptomsc
7.7 (0.6)
4.0 (0.6)
SIPS General Symptomsc
11.6 (1.0)
5.9 (0.8)
Global Assessment of Functioningc
36.7 (2.8)
56.3 (3.2)
GF:Role
4.6 (0.3)
5.6 (5.7)
GF:Social
5.6 (0.3)
6.9 (0.3)
QLS Instrumental
2.7 (0.4)
3.7 (0.4)
QLS Interpersonal
3.3 (0.3)
4.2 (0.2)
QLS Intrapsychic
3.6 (0.2)
4.2 (0.2)

Outcome Variable

Adjusted Scoresa

Table 2. Continued
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Fig. 2. Regression-discontinuity outcome. CLR vs CHR (small arrow), p = .0034. CLR vs EFEP (large arrow), p < .0001. Dashed line
extending from solid line represents expected regression outcome in the range of CHR and EFEP baseline values, based on CLR values.
Regression lines are plotted through group averages with parallel slopes estimated from the primary analysis model. Vertical arrow
lengths approximate effect sizes. CHR, clinically higher risk; CLR, clinically lower risk; EFEP, early first-episode psychosis.

though not for the subgroups (CHR + EFEP, F = 4.79,
p = .0091; CHR: β = 1.86, SE = 2.88, p = .517; EFEP: β
= 8.19, SE = 4.64, p = .079). Unadjusted change scores
at 24 months for GAF increased significantly in all
groups, ending at the same level, though change scores
over 24 months were larger in the FACT-treated subgroups (CLR: 60.2 [Δ = 10.65; t = 4.360, df = 53, p <
.001]; CHR: 59.0 [Δ = 17.47; t = 10.945, df = 131, p <
.001]; EFEP: 62.4 [Δ = 34.55; t = 10.497, df = 32, p <
.001]). Adjusting for the allocation variable, GF scores
for both the EFEP and CHR subgroups did not differ significantly from CLR (see table 2). Both mean
GF:Role and GF:Social unadjusted scores increased
significantly from baseline to 24 months among CHR
(GF:S: t = 7.143, df = 118, p < .0001; GF:R: t = 2.202,
df = 118, p = .030) and EFEP (GF:S: t = 3.832, df = 31,
p = .001; GF:R: t = 2.371, df = 31, p = .024) groups
but not among the CLR group (ns, nonsignificant).
The degree of change was greatest for the EFEP subgroup (GF:S: CLR, 5.1% vs CHR, 15.3% and EFEP,
22.3%; GF:R: 0.2% vs 12.1% and 23.6%, respectively;
see figure 3).
Likewise, adjusting for the allocation variable, QLS
outcomes for both the EFEP and CHR subgroups did
not differ significantly from CLR. QLS unadjusted scores
improved significantly from baseline in the CHR (QLS
sum score: t = 7.508, df = 127, p < .0001) and EFEP
(t = 3.641, df = 28, p = .001) groups, but not for the CLR
group (t = 1.402, df = 53, p = .167).
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Those in school or working at baseline and 24 months
were, respectively, 88% and 79% in CLR compared with
84% and 83% in CHR + EFEP (see table 3).
Between baseline and 24 months, the proportion of
subjects who increased their level of participation in work
or school (from neither to one or both or from either to
both) was 20.6% (35/170) in the CHR + EFEP cohort
compared with 7.0% (4/57) in the CLR cohort. The OR
comparing these 2 proportions was significant (OR: 3.44,
95% CI: 1.16, 11.0, p = .025). Those in school and working
at baseline and 24 months were, respectively, 11% and 9%
in CLR compared with 11% and 18% in CHR + EFEP.
Global Outcome
The GTP, incorporating all 10 clinical and functional variables, demonstrated FACT to be superior to CLR community treatment (CHR + EFEP: F = 7.50, p = .0007;
CHR: β = 0.38, SE = 0.17, p = .024; EFEP: β = 1.0510,
SE = 0.2787, p = .0002).
Attrition and Site Effects
Though the attrition rate was 34% at 2 years, there
were no significant differences in baseline measures
between completers and those with missing data at
24 months for any of the 10 outcome measures. The
attrition rate was 27% at 6 months, 29% at 12 months,
and 34% at 24 months. At each point, the completion
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Positive symptom sum score
25.00

20.00

15.00

10.00

5.00

0.00
Baseline

6 Months
CLR

12 months
CHR

24 months

EFEP

Negative symptoms sum score
16.00

14.00

12.00

10.00

8.00

6.00

4.00

2.00

0.00
Baseline

6 Months

12 months

24 months

Fig. 3. Symptom and functional levels across study intervals. CLR, clinically lower risk, baseline n = 87. CHR, clinically higher risk,
baseline n = 205. EFEP, early first-episode psychosis, baseline n = 45. Data points represent mean raw (unadjusted) scores for each
subgroup at the respective assessment date.
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Global Assessment of Functioning (GAF) score
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Role Functioning
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6 Months
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Fig. 3. Continued

rate was lowest for the CLR, higher for the CHR group,
and highest for the EFEP group (eg, at 12 months, the
respective percentages were 66%, 71%, and 80%). Site
was significant as a main effect (F = 4.29 on [5,259] df,
p = .0009). However, there was no significant site by
group interaction.
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Discussion
Summary of Findings
EDIPPP was established to test the effectiveness of early
identification and intervention with FACT for youth at
high risk of onset of an initial psychotic episode. Beyond
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Fig. 3. Continued
Table 3. Participation in School and Work at Baseline and 24 mo
In School Only

Working Only

Both Work and Schoolb

Either or Both

Group (N)a

Baseline

24 mo

Baseline

24 mo

Baseline

24 mo

Baseline

24 mo

CLR (57)
CHR (136)
EFEP (34)
CHR + EFEP (170)

40 (70%)
96 (71%)
23 (68%)
119 (70%)

30 (53%)
78 (57%)
14 (41%)
92 (54%)

4 (7%)
3 (2%)
2 (6%)
5 (3%)

10 (18%)
15 (11%)
4 (12%)
19 (11%)

6 (11%)
16 (12%)
2 (6%)
18 (11%)

5 (9%)
22 (16%)
8 (24%)
30 (18%)

50 (88%)
115 (85%)
27 (79%)
142 (84%)

45 (79%)
115 (85%)
26 (76%)
141 (83%)

Notes: Entries are frequencies (percentages). Abbreviations are explained in the first footnote to table 1.
Includes only subjects with nonmissing school and work status.
b
“Both” includes working and in school simultaneously.
a

testing clinical and functional outcomes in real-world settings, it also intended to assess feasibility of identification
across whole communities and across a wide spectrum of
the United States and its diverse populations. The participating sites educated key professionals in identification
of early psychosis and provided FACT treatment for 250
youth. Treatment results included significant effects for
reduction of positive, negative, disorganized, and general symptoms, increases in GAF, and superior overall
improvement for FACT, compared to community care.
Over the 24-month period, the FACT group increased
their level of participation in work or school by 21%
compared to 7% in the CLR group. Unexpectedly, effects
for symptoms, GAF, and global outcomes were larger for
the group having very early psychosis than in the clinical
high-risk group.

Strengths and Threats to Validity
This study’s strengths include the large and diverse
sample, independent assessment by reliable raters blind
to assignment, high fidelity for the key treatment component, successful equalization of lower and higher risk
subsamples in the regression-discontinuity analysis, and
dissemination of a comprehensive model to 5 other cities, 2 of which sites’ staff had no prior experience with
early psychosis. Caution is warranted because of the
quasi-experimental design. Although it is considered the
strongest of the quasi-experimental approaches, other
possible interpretations of our findings could hold.31 The
supplementary data contain further discussion of the key
assumptions underpinning the regression-discontinuity
analysis and evidence in support of their validity. The
attrition rate was 27% at 6 months, 29% at 12 months,
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and 34% at 24 months. There were no significant differences between completers and noncompleters on any of
the baseline demographic variables, and the regression
analyses used data for each subject at any point at which
they were assessed. Nevertheless, caution is indicated in
generalizing the results.
Comparison to Other Studies
These results strengthen the evidence that early intervention to prevent onset or progression of psychosis in youth
is effective, warrants expansion of practice, and constitutes
an advance for public health. It may alleviate some of the
ambiguity of results across studies, which has been cited
as contrary evidence for efficacy.38 More specifically, of the
trials included in a recent meta-analysis, 3 had single-trial
significant effects, 2 of which applied PMFG treatment of
the type used in EDIPPP.5,17,18 This study also strengthens
the evidence for family intervention in early psychosis,
continuing a record of efficacy in established schizophrenia and first-episode psychosis.39–41 The conversion rate,
6.3% over 2 years, compares favorably to the 29% found
in the most recent meta-analysis of untreated naturalistic
or standard treatment control samples and the 7.6% 1-year
rate in treated subsamples in randomized controlled trials
to date.5,22 For studies using the SIPS, the respective rates
have been 26.4% and 10.3% at 6 or 12 months in 2 RCTs12,42
and 35% at 30 months in the North American Prodromal
Longitudinal Study naturalistic follow-up study.43 It suggests that this approach is relevant to the United States,
because only one of the treatment studies cited was conducted here.5,12
Conclusions
Early identification and intervention with FACT during
the period prior to onset of frank and lengthy psychosis
was found to be effective in improving symptoms, GAF,
and overall outcomes in 6 US cities. The diversity of
the sample and sites, the scale of the treatment effects,
and the weight of efficacy evidence from the most recent
meta-analyses suggests that early intervention, particularly prior to onset of frank psychosis, could lead to
reduction in total burden of disease.
Supplementary Material
Supplementary material is available at http://schizophreniabulletin.oxfordjournals.org.
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